Billiontoone, Inc. (BLLN) Stock Price & Analysis

Billiontoone, Inc. (BLLN) fell 0.33% to USD 99.06 as of September 9, 2026 at 12:37 UTC, according to Nexqual real-time market data.

BLLN last closed at USD 99.39; the session ranged USD 96.16–102.37 on volume of 590,275 shares. Market capitalization is $4.67B, with a 52-week range of USD 61.96–150.44 (NMS). Source: Nexqual, September 9, 2026 at 12:37 UTC.

Key Statistics (as of September 9, 2026 at 12:37 UTC)

Technical Analysis (BLLN)

Nexqual's technical model rates BLLN "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of September 9, 2026 at 12:37 UTC.

Analyst Ratings (BLLN)

Wall Street analysts rate BLLN "Buy" based on 8 analysts, with a mean price target of USD 119.75 (range USD 90–145), per Nexqual as of September 9, 2026 at 12:37 UTC.

Earnings (BLLN)

Recent Earnings History

Source: Nexqual, September 9, 2026 at 12:37 UTC.

Financials & Fundamentals (BLLN)

Source: Nexqual, September 9, 2026 at 12:37 UTC.

Financial Health Score (BLLN)

Nexqual rates Billiontoone, Inc.'s overall financial health "Solid" across five dimensions, as of September 9, 2026 at 12:37 UTC.

Ownership (BLLN)

Source: Nexqual, September 9, 2026 at 12:37 UTC.

Leadership (BLLN)

Billiontoone, Inc. is led by Oguzhan Atay (age 36), Co-Founder, Chairman & CEO, per Nexqual as of September 9, 2026 at 12:37 UTC.

Major Backers & Investors (BLLN)

Notable institutional backers of Billiontoone, Inc. include Adams Street Partners, LLC, Price (T.Rowe) Associates Inc, Baillie Gifford, according to Nexqual as of September 9, 2026 at 12:37 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, September 9, 2026 at 12:37 UTC.

From Billiontoone, Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)

Key Strengths & Strategy (as disclosed to the SEC)

• Each of these steps introduces technical noise that makes it harder for traditional sequencing technologies to accurately quantify the absolute and relative abundance of cfDNA sequences in the biological specimen, resulting in lower sensitivity and specificity. 6 Table of Contents Our Proprietary Single-Molecule Next-Generation Sequencing Platform (smNGS) We have developed a transformative technology platform that redefines the possibilities of cfDNA analysis.
• In the future we may seek FDA approval for certain of our tests, in particular, Northstar Select, which could provide us with competitive advantages such as including enhanced reimbursement through Advanced Laboratory Diagnostic Test (ALDT) pricing; however, it would also subject us to additional regulatory requirements, which can be costly.
• Our Technology Our smNGS platform leverages proprietary and patent-protected technologies that allow us to detect previously undetectable diseases and support physicians developing and managing treatment plans for patients.
• For instance, QCTs detect cross-contamination down to the level of <0.001% and thereby enable the creation of carefully constructed and automated end-to-end laboratory workflows, including special laboratory infrastructure, that prevent such cross-contamination that could otherwise be a bottleneck on sensitivity and specificity of an assay.

Partnerships

• UNITY Fetal Antigen CTA NIPT In December 2023, we announced a global partnership with Johnson & Johnson to provide our UNITY Fetal Antigen clinical trial assay (CTA) in their AZALEA Phase 3 clinical trial of nipocalimab in pregnancies at risk for severe HDFN.
• In collaboration with University of Florida, we are conducting a 100-patient prospective study examining the clinical validity of Northstar Response focusing specifically on advanced gastrointestinal tumors.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 12:37 UTC. This page is informational and not investment advice.